The deal is part of Sanofi's effort to recover ground in the diabetes market.
Sanofi and Hanmi Pharmaceuticals Co. Ltd today announced a $4.2 billion in which Sanofi will gain exclusive worldwide rights to develop and commercialize Hanmi’s novel diabetes treatments.
These include a long acting glucagon-like peptide-1 (GLP-1) receptor agonist, a weekly insulin and a GLP-1 and insulin that act in combination. Collectively, they are known as Hanmi’s Quantum project.
Hanmi, based in South Korea, will retain an option to commercialize its products in Korea and China.
The deal, announced jointly in Paris and Seoul, is seen as a way for Sanofi to revive its diabetes business to compete with Novo Nordisk and Eli Lilly, particularly in the area of long-acting therapies.
Hanmi’s efpegelenatide, a late-stage long acting GLP-1 RA, was featured at the 75th Scientific Sessions of the American Diabetes Association in June.
Pascale Witz
"The agreement to develop these three investigational diabetes medicines confirms Sanofi's long-term commitment to people with this disease," said , executive vice president, Sanofi, who will lead the Global Diabetes and Cardiovascular Care Business Unit in the company's new organizational structure.
"We now have the opportunity to expand our existing portfolio by including medicines that are administered weekly as well as daily, which could extend our reach in basal insulin and expand our GLP-1-RA and GLP-RA/insulin combination prospects. In these ways, we aim to complement our current offerings and work to serve a broader patient population."
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen